- Correction
- Open Access
- Published:
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
The Journal of Headache and Pain volume 23, Article number: 64 (2022)
Correction: J Headache Pain 23, 46 (2022)
https://doi.org/10.1186/s10194-022-01396-x
Following the publication of the original article [1], we were notified of a mistake in the abstract: the 100% response rate in HFEM at week 12 is 5.9% (as correctly reported in figure 3) and NOT 9.9% as reported in the abstract and page 5.
The original article has been corrected.
Reference
Barbanti et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23:46. https://doi.org/10.1186/s10194-022-01396-x
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Barbanti, P., Egeo, G., Aurilia, C. et al. Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23, 64 (2022). https://doi.org/10.1186/s10194-022-01434-8
Published:
DOI: https://doi.org/10.1186/s10194-022-01434-8